Yi Wang

Dr. Yi Wang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2023 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
QXQingyun Xu
Qingyun Xu
YJYiming Jia
Yiming Jia
YWYi Wang
Yi Wang
PYPinni Yang
Pinni Yang
LSLulu Sun
Lulu Sun
Zhengbao ZhuZhengbao Zhu
Zhengbao Zhu

5 September 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
QXQingyun Xu
Qingyun Xu
LSLulu Sun
Lulu Sun
YWYi Wang
Yi Wang
RWRuirui Wang
Ruirui Wang
YJYiming Jia
Yiming Jia
Zhengbao ZhuZhengbao Zhu
Zhengbao Zhu
Background: Chitinase‐3 like protein 1 (CHI3L1, YKL‐40) was reported to be implicated in the development of ischemic stroke, but whether the association between them was causal remained unclear. We conducted a 2‐sample Mendelian randomization study to explore the associations of genetically determined plasma YKL‐40 with ischemic stroke and its subtypes (large artery stroke, small vessel stroke, and cardioembolic stroke). Methods and Results: Based on genome‐wide association study data of 3394 European‐descent individuals, we selected 13 single‐nucleotide polymorphisms associated with plasma YKL‐40 as genetic instruments. Summary data about ischemic stroke and its subtypes were obtained from the Multiancestry Genome‐wide Association Study of Stroke Consortium, involving 34 217 ischemic stroke cases and 406 111 controls of European ancestry. We used the inverse‐variance weighted method followed by a series of sensitivity analyses to assess the causal associations of plasma YKL‐40 with ischemic stroke and its subtypes. The primary analysis showed that genetically determined high YKL‐40 levels were associated with increased risks of large artery stroke (odds ratio [OR], 1.08 [95% CI, 1.04–1.12]; P =1.73×10 −4 ) and small vessel stroke (OR, 1.05 [95% CI, 1.01–1.09]; P =7.96×10 −3 ) but not with ischemic stroke or cardioembolic stroke. Sensitivity analyses further confirmed these associations, and Mendelian randomization‐Egger indicated no evidence of genetic pleiotropy. In addition, supplementary analysis based on the summary data from the Olink proximity extension assay cardiovascular I (Olink CVD‐I) panel showed that high YKL‐40 levels were positively associated with the risks of large artery stroke (OR, 1.15 [95% CI, 1.08–1.22]; P =4.16×10 −6 ) but not with small vessel stroke. Conclusions: Genetically determined high plasma YKL‐40 levels were causal associated with increased risks of large artery stroke.

1 June 2024 in Stroke
Verified
Journal Article
Closed access
PDF file
QXQingyun Xu
Qingyun Xu
DGDaoxia Guo
Daoxia Guo
MSMengyao Shi
Mengyao Shi
YWYi Wang
Yi Wang
PYPinni Yang
Pinni Yang
Zhengbao ZhuZhengbao Zhu
Zhengbao Zhu
BACKGROUND: Observational studies suggest that hepatocyte growth factor (HGF) is associated with the risk and prognosis of ischemic stroke, but the causality of these associations remains unclear. Therefore, we conducted Mendelian randomization (MR) analyses to explore the associations of genetically determined plasma HGF levels with the risk and prognosis of ischemic stroke. METHODS: A total of 13 single-nucleotide polymorphisms associated with plasma HGF were selected as genetic instruments based on the data from a genome-wide association study with 21 758 European participants. Summary data about the risk of ischemic stroke were obtained from the MEGASTROKE (Multiancestry Genome-Wide Association Study of Stroke) Consortium with 34 217 ischemic stroke cases and 406 111 controls of European ancestry, and summary data about the prognosis of ischemic stroke were obtained from the GISCOME study (Genetics of Ischaemic Stroke Functional Outcome) with 6165 European patients with ischemic stroke. We conducted an inverse-variance weighted Mendelian randomization analysis followed by a series of sensitivity analyses to evaluate the associations of genetically determined plasma HGF with the risk and prognosis of ischemic stroke. RESULTS: The primary analyses showed that genetically determined high HGF was associated with an increased risk of ischemic stroke (odds ratio per SD increase, 1.11 [95% CI, 1.04–1.19]; P =1.10×10 −3 ) and poor prognosis of ischemic stroke (odds ratio per SD increase, 2.43 [95% CI, 1.76–3.52]; P =6.35×10 −8 ). In the secondary analysis, genetically determined plasma HGF was associated with a high risk of large atherosclerotic stroke (odds ratio per SD increase, 1.39 [95% CI, 1.18–1.63]; P =5.08×10 −5 ) but not small vessel stroke and cardioembolic stroke. Mendelian randomization-Egger regression showed no directional pleiotropy for all associations, and the sensitivity analyses with different Mendelian randomization methods further confirmed these findings. CONCLUSIONS: We found positive associations of genetically determined plasma HGF with the risk and prognosis of ischemic stroke, suggesting that HGF might be implicated in the occurrence and development of ischemic stroke.

15 August 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
YWYi Wang
Yi Wang
YJYiming Jia
Yiming Jia
QXQingyun Xu
Qingyun Xu
PYPinni Yang
Pinni Yang
LSLulu Sun
Lulu Sun
Zhengbao ZhuZhengbao Zhu
Zhengbao Zhu
Background: High plasma prekallikrein was reported to be associated with increased risks of stroke, but the causality for these associations remains unclear. We aimed to investigate the associations of genetically predicted plasma prekallikrein concentrations with all‐cause stroke, ischemic stroke, 3 ischemic stroke subtypes, and intracerebral hemorrhage (ICH) using a 2‐sample Mendelian randomization approach. Methods and Results: Seven independent prekallikrein‐related single‐nucleotide polymorphisms were identified as genetic instruments for prekallikrein based on a genome‐wide association study with 1000 European individuals. The summary statistics for all‐cause stroke, ischemic stroke, and ischemic stroke subtypes were obtained from the Multiancestry Genome‐wide Association Study of Stroke Consortium with 40 585 cases and 406 111 controls of European ancestry. The summary statistics for ICH were obtained from the ISGC (International Stroke Genetics Consortium) with 1545 ICH cases and 1481 controls of European ancestry. In the main analysis, the inverse‐variance weighted method was applied to estimate the associations of plasma prekallikrein concentrations with all‐cause stroke, ischemic stroke, ischemic stroke subtypes, and ICH. Genetically predicted high plasma prekallikrein levels were significantly associated with elevated risks of all‐cause stroke (odds ratio [OR] per SD increase, 1.04 [95% CI, 1.02–1.06]; P =5.44×10 −5 ), ischemic stroke (OR per SD increase, 1.05 [95% CI, 1.03–1.07]; P =1.42×10 −5 ), cardioembolic stroke (OR per SD increase, 1.08 [95% CI, 1.03–1.12]; P =3.75×10 −4 ), and small vessel stroke (OR per SD increase, 1.11 [95% CI, 1.06–1.17]; P =3.02×10 −5 ). However, no significant associations were observed for genetically predicted prekallikrein concentrations with large artery stroke and ICH. Conclusions: This Mendelian randomization study found that genetically predicted high plasma prekallikrein concentrations were associated with increased risks of all‐cause stroke, ischemic stroke, cardioembolic stroke, and small vessel stroke, indicating that prekallikrein might have a critical role in the development of stroke.

18 December 2023 in Cerebral Cortex
Verified
Journal Article
Closed access
PDF file
YWYi Wang
Yi Wang
OSOuxi Shen
Ouxi Shen
QXQingyun Xu
Qingyun Xu
LSLulu Sun
Lulu Sun
YJYiming Jia
Yiming Jia
Zhengbao ZhuZhengbao Zhu
Zhengbao Zhu
Brain imaging-derived phenotypes have been suggested to be associated with amyotrophic lateral sclerosis in observational studies, but whether these associations are causal remains unclear. We aimed to assess the potential bidirectional causal associations between imaging-derived phenotypes and amyotrophic lateral sclerosis using bidirectional 2-sample Mendelian randomization analyses. Summary statistics for 469 imaging-derived phenotypes (33,224 individuals) and amyotrophic lateral sclerosis (20,806 cases and 59,804 controls) were obtained from 2 large-scale genome-wide association studies of European ancestry. We used the inverse-variance weighted Mendelian randomization method in the main analysis to assess the bidirectional associations between imaging-derived phenotypes and amyotrophic lateral sclerosis, followed by several sensitivity analyses for robustness validation. In the forward Mendelian randomization analyses, we found that genetically determined high orientation dispersion index in the right cerebral peduncle was associated with the increased risk of amyotrophic lateral sclerosis (odds ratio = 1.30, 95% confidence interval = 1.16–1.45, P = 2.26 × 10−6). In addition, the reverse Mendelian randomization analysis indicated that amyotrophic lateral sclerosis had no effect on 469 imaging-derived phenotypes. Mendelian randomization-Egger regression analysis showed no directional pleiotropy for the association between high orientation dispersion index in the right cerebral peduncle and amyotrophic lateral sclerosis, and sensitivity analyses with different Mendelian randomization models further confirmed these findings. The present systematic bidirectional Mendelian randomization analysis showed that high orientation dispersion index in the right cerebral peduncle might be the potential causal mediator of amyotrophic lateral sclerosis, which may provide predictive guidance for the prevention of amyotrophic lateral sclerosis. Further studies are warranted to replicate our findings and clarify the underlying mechanisms.

1 October 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
YWYi Wang
Yi Wang
PYPinni Yang
Pinni Yang
Zhengbao ZhuZhengbao Zhu
Zhengbao Zhu
Hao PengHao Peng
Hao Peng
XBXiaoqing Bu
Xiaoqing Bu
JHJiang He
Jiang He
Background: Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet‐mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long‐term clinical outcomes within 2 years after ischemic stroke onset is modulated by aPLs. Methods and Results: A total of 2938 patients with ischemic stroke were included in this prospective cohort study. Cox proportional hazards regression models were used to assess the association between the baseline PLT stratified by aPLs status and 2‐year clinical outcomes after stroke onset, and an interaction effect between PLT and aPLs on clinical outcomes was tested by likelihood ratio test. There was a significant interaction effect of aPLs and PLT on recurrent stroke ( P interaction =0.002) and cardiovascular events ( P interaction =0.001) within 2 years after stroke onset. After multivariate adjustment, high PLT was associated with increased risks of recurrent stroke (hazard ratio [HR], 2.78 [95% CI, 1.03–7.45]; P trend =0.039) and cardiovascular events (HR, 2.58 [95% CI, 1.12–5.90]; P trend =0.024) when 2 extreme tertiles were compared among patients with aPL positive, but not among those with aPL negative. Conclusions: The aPLs had a modifying effect on the association between PLT and clinical outcomes within 2 years after ischemic stroke onset. Increased PLT was associated with recurrent stroke and cardiovascular events after ischemic stroke onset among patients with aPL positive, but not in those with aPL negative.